Polylysine-Containing Hydrogel Formulation of Fuzapladib, Inhibitor of Leukocyte-Function Associated Antigen-1 (LFA-1) Activation, for Sustained Release
The aim of the present study was to develop an injectable hydrogel (HG) formulation of fuzapladib sodium (FZP), an animal drug for acute pancreatitis (AP), with the use of polyethyleneoxide (PEO) and polylysine (pLys), a cationic polymer. A mixture of pLys and FZP was added to PEO to prepare an HG formulation, and the formulation was optimized by release test and viscosity measurements. Circular dichroism (CD) and infrared absorption (IR) spectral analyses were applied to clarify the intermolecular interactions between FZP and pLys. The pharmacokinetic behavior of FZP was evaluated after a subcutaneous administration of FZP samples (2.0 mg-FZP/kg) to rats. Although the immediate release of FZP was observed for the HG formulation, the addition of pLys at a 20-fold amount of FZP or higher led to the sustained release of FZP. Considering release behavior, the concentration of pLys was optimized as 100-fold that of FZP in the HG formulation. CD and IR spectroscopic analyses of FZP and/or pLys demonstrated an intermolecular interaction between FZP and pLys, as evidenced by the slight spectral transition. After a subcutaneous administration of HG formulation containing pLys to rats, compared with FZP alone, significant differences were observed in the pharmacokinetic behavior with a decrease of Cmax from 2.3 to 0.9 mg/mL and slower elimination kinetics. HG formulation using pLys might be a viable dosage option for FZP for the treatment of AP in animals.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Molecules (Basel, Switzerland) - 28(2023), 14 vom: 11. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Higuchi, Koji [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
25104-18-1 |
|---|
| Anmerkungen: |
Date Completed 31.07.2023 Date Revised 01.08.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/molecules28145325 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360130690 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360130690 | ||
| 003 | DE-627 | ||
| 005 | 20231226082345.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/molecules28145325 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1200.xml |
| 035 | |a (DE-627)NLM360130690 | ||
| 035 | |a (NLM)37513199 | ||
| 035 | |a (PII)5325 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Higuchi, Koji |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Polylysine-Containing Hydrogel Formulation of Fuzapladib, Inhibitor of Leukocyte-Function Associated Antigen-1 (LFA-1) Activation, for Sustained Release |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.07.2023 | ||
| 500 | |a Date Revised 01.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The aim of the present study was to develop an injectable hydrogel (HG) formulation of fuzapladib sodium (FZP), an animal drug for acute pancreatitis (AP), with the use of polyethyleneoxide (PEO) and polylysine (pLys), a cationic polymer. A mixture of pLys and FZP was added to PEO to prepare an HG formulation, and the formulation was optimized by release test and viscosity measurements. Circular dichroism (CD) and infrared absorption (IR) spectral analyses were applied to clarify the intermolecular interactions between FZP and pLys. The pharmacokinetic behavior of FZP was evaluated after a subcutaneous administration of FZP samples (2.0 mg-FZP/kg) to rats. Although the immediate release of FZP was observed for the HG formulation, the addition of pLys at a 20-fold amount of FZP or higher led to the sustained release of FZP. Considering release behavior, the concentration of pLys was optimized as 100-fold that of FZP in the HG formulation. CD and IR spectroscopic analyses of FZP and/or pLys demonstrated an intermolecular interaction between FZP and pLys, as evidenced by the slight spectral transition. After a subcutaneous administration of HG formulation containing pLys to rats, compared with FZP alone, significant differences were observed in the pharmacokinetic behavior with a decrease of Cmax from 2.3 to 0.9 mg/mL and slower elimination kinetics. HG formulation using pLys might be a viable dosage option for FZP for the treatment of AP in animals | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a acute pancreatitis | |
| 650 | 4 | |a fuzapladib | |
| 650 | 4 | |a hydrogel | |
| 650 | 4 | |a polylysine | |
| 650 | 4 | |a sustained release | |
| 650 | 7 | |a Polylysine |2 NLM | |
| 650 | 7 | |a 25104-18-1 |2 NLM | |
| 650 | 7 | |a Hydrogels |2 NLM | |
| 650 | 7 | |a Delayed-Action Preparations |2 NLM | |
| 650 | 7 | |a Lymphocyte Function-Associated Antigen-1 |2 NLM | |
| 700 | 1 | |a Yamada, Kohei |e verfasserin |4 aut | |
| 700 | 1 | |a Kihara, Tsubasa |e verfasserin |4 aut | |
| 700 | 1 | |a Makino, Keisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Sasaki, Kenta |e verfasserin |4 aut | |
| 700 | 1 | |a Shindo, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Shikama, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Hideyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Onoue, Satomi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecules (Basel, Switzerland) |d 2004 |g 28(2023), 14 vom: 11. Juli |w (DE-627)NLM172073448 |x 1420-3049 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:14 |g day:11 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/molecules28145325 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 14 |b 11 |c 07 | ||